Hema.to, a Munich-based digital medtech company, secured €3.6M in funding led by LUMO Labs, aimed at advancing its AI-supported platform for rapid diagnosis of blood cancers like leukaemia and lymphoma. The company's technology significantly decreases analysis time, from 20 minutes to just one, easing the burden on clinical labs facing high workloads and staff shortages. By enhancing efficiency in diagnosing severe diseases, Hema.to is tapping into a multi-billion dollar global market, creating opportunities both in Europe and internationally, as supported by investors like Bayern Kapital.
Munich-based Hema.to has raised €3.6M in funding to enhance its AI-supported analysis platform for rapid diagnosis of leukemia and lymphoma.
Hema.to’s technology cuts blood analysis time dramatically, thereby alleviating pressure on clinical laboratories and improving patient outcomes in detecting serious diseases.
General concern over rising sample volumes and staff shortages in clinical labs has amplified the importance of Hema.to's solution for timely diagnoses in a multi-billion dollar market.
Bayern Kapital sees significant potential in Hema.to’s AI technology, which is designed for use in Europe and internationally, targeting crucial diagnostics in healthcare.
Collection
[
|
...
]